Armen Panossian
Chief Executive Officer
Yes, so I would say there's three big picture opportunity sets that I think go OCSL could participate in.The first, our middle market sponsor finance deals. We've done some of those today. Frankly, we are a little bit concerned about some of the lending practices and deterioration and credit quality, legal protections, et cetera, that we see broadly in that space. So, we are not all of a sudden going to hit the gas and put in a bunch of middle market sponsor finance deals, just to be able to get more investor or more levered in this structure.However, if we do see middle market sponsor deals that are non-cyclical, well-structured and offer appropriate compensation given the risk, then we'll take a very close look and add those to the portfolio and we did some of those deals over the last few months.So, that's kind of the first broad area and I would say, that's going to be unit tranche deals. That's going to be first lien deals maybe some second lien as well, but I would say predominantly, firstly, the unit tranche in that space, but we're not going to stretch for risk and we're not going to take on deeply cyclical businesses to get invested, especially considering the leverage levels creeping higher and higher in that area.The second area is the non-sponsor area. These are the bespoke financings that are industries or businesses that are either harder to understand by traditional cash flow lenders, or have been shunned by the markets and in those situations oddly enough, the debt to total enterprise value tends to be much lower than even in the middle market sponsor area.And the challenges maybe they have a cash flow issue, maybe they need a bridge from their current situation through a cyclical issue that they're seeing. There are a lot of story credits out there that could use a highly structured solution. We have done a few of those as well.We mentioned G-Power, CIV Logistics. Both of those are situations where we took a very tight view of credit. We worked very closely with the borrower on structure, and were able to deliver returns, there were yields there that I think are better than average, with a lot of downside protection.And so, where we those types of deals are harder to predict, in terms of timing, but when we see them, we know what we like about them. And we get a pretty good sense pretty quickly, whether there's an opportunity there because we are very quick to turn around a term sheet that is that is quite is quite deep in terms of its legal protections and other structural considerations.And to the extent the borrower doesn't need it. We're doesn't want it, then we're fine with moving on. But those are the opportunities that are, I think that will be most differentiated for us, vis-a-vis, a lot of other BDCs you might see in the market, and we're looking to do as much of that as possible. And I think being an Oaktree puts us in a very strong position to be able to find that type of deal flow.The third area, our middle market and other loans that have been syndicated and we do take a look at that market. That market is trading very rich right now. It's, the loans that that we would find interesting by and large are trading at or near par. So, there isn't much to do there.But there are periods of time, where rating sensitive owners of loans, have some technical flow problems and that creates a technical dislocation in the broadly syndicated markets or the tradable loan markets that we could find interesting from time-to-time and we do participate in that area, we did buy some secondary loans in the last few months that had traded off for what we think were more momentary or technical issues rather than fundamental longer term problems.And so we benefit from having a trading desk and a trading operation here that servicing billions of capital in our opportunistic funds and are in our other strategies, and therefore our market connectivity is very, very high and we get treated very, very well in the secondary and primary markets in the tradable credit markets as well.So, we're tapping all three of those opportunities at different points in time, there may be one or two of those opportunities that are more attractive than the third. But by and large, where we get most excited is when the markets are in the greatest amount of trouble, both in terms of secondary trading and in terms of these bespoke financings, where the capital markets are shut down and we are a - our capital is patient or has been patient and we're able to take advantage of those opportunities.I can't dimensionalize or give a forward guidance on what returns should look like. But you could see that from some of our more opportunistic deals like a CIG Logistics at LIBOR plus 850. Those types of opportunities are out there are Sorento investment, as you know, we did a highly structured loan in that situation. It comes with some equity upside as well.And that was done because we have talented individuals here that understand life sciences, understand that clinical stage development process and how to value technology that has developed through that process.And so, we will take advantage of our depth and expertise, both in terms of structuring and in terms of particular industries, I just can't predict the timing of it, and I can't predict the outcome of it. But when we do see it like a Sorento like a CIG, like others, we are able to get meaningfully better unlevered returns or asset yields on those types of loans.